Remember when yesterday's brief told you the AI trade sat out the biggest Dow rally in years — Nvidia down 3.1% on a day everything else ripped? That was not a footnote. That was the warning. One day later the thing it was warning about arrived all at once, and the rally is gone. Fair warning before we start — this one runs longer than usual, because Thursday only makes sense as the last step of an escalation that has been building for months.
It started long before election week. Back in July, New York's governor ordered state regulators to stop granting new permits for large-scale data centers for up to a year, and candidates in at least a dozen states campaigned on similar pauses — angry about electricity bills, noise, and who pays for the grid these buildings need. The AI buildout's valuations, meanwhile, were priced for a world where every permit gets granted at full speed.
Then came Monday, November 2. Before a single vote was counted, the Nasdaq-100 had already slipped into a correction as investors got wary of Big Tech's AI spending and the thin evidence of payback for it. The ground was soft before anyone lit a match.
Then came Tuesday, November 3. Democrats swept both chambers of Congress and the governorships that matter most for this story — including Texas, which holds roughly 27% of all planned U.S. data-center capacity, where the winning campaign had called for a statewide moratorium on new data-center permits. Goldman Sachs reckons the states likely to add restrictions hold about 45% of planned U.S. capacity, and UBS estimates around 30% of the capacity additions expected in 2028 could face construction pauses.
Then came Wednesday, November 4, and the market's first read was relief. The Dow roared 1,569 points on gridlock logic, oil crashed 8% on hopes the Iran war winds down, and the hyperscalers — the companies that buy the AI hardware — rose, Microsoft up 6.7%. But look at who fell on that green day: the builders. Hut 8, with most of its construction in Texas, fell 23%. Nvidia fell 3.1%. The sellers already knew which side of the trade the election hit. After the close, Qualcomm handed them the match: a fourth-quarter beat on the surface, but handset chip revenue down 26% as Apple-related sales fade.
Then came Thursday, November 5, and two more threads pulled tight at once. Overnight, oil reversed: tanker attacks in the Gulf and the Strait of Hormuz — at least five vessels reporting incidents since Sunday, running close to a record pace — pushed Brent up $3.67 to settle at $98.29 and WTI up $2.40 to $90.52. The war premium Wednesday buried came straight back. And Thursday morning's labor data gave sellers no cover at all: initial jobless claims fell 6,000 to 189,000, the lowest reading since 1969, productivity rose 3.6%, and unit labor costs fell 0.7% — an economy that is not cracking, which means this selloff was never about the economy.
But the real thread running through it was permission. Nothing about the chips changed on Thursday — demand for compute did not fall 12% between breakfast and the close. What fell was the price of an assumption: that America would keep saying yes to the buildout as fast as the valuations required.
The day, in one list
- Philadelphia Semiconductor Index — 9,011.14 — down 12.25%, its second-biggest fall on record and its worst day since March 2020
- Nasdaq Composite — 24,315.00 — down 5.52%, closing in correction, 11.9% below its October 6 record
- S&P 500 — 7,353.73 — down 4.36%, its worst day since April 2025; all 11 sectors down, technology down 7.3%
- Dow Jones Industrial Average — 51,523.06 — down 1,833.06 points, or 3.44%, more than erasing Wednesday's gain
- SanDisk — down 22.26%; Micron — down 17.46%; AMD — down 17.26%
- Nvidia — $181.60 — down 9.26%; Qualcomm — $156.75 — down 9.49% on the handset miss
- VIX — 28.09 — up about 69% in a day, from 16.61
- Brent crude — $98.29 — up 3.88% on the tanker attacks; WTI — $90.52 — up 2.72%
- Bitcoin — $76,088 — down 5.49%; Ethereum — $2,238 — down 7.70%; total crypto market — about $2.55 trillion, down about 5%
- Crypto Fear & Greed Index — 28, Fear — down from 50, Neutral, the day before
What got tested, what got hit, what is still standing
Crypto took the same hit through the side door. More than a billion dollars of leveraged positions were liquidated, the bulk of them longs — people betting up, forced out. Spot Bitcoin ETFs saw $430.2 million walk out on Thursday and Ethereum ETFs another $100 million; not one of the twelve Bitcoin funds took in money. And rate traders quietly repriced too: the odds of a December Fed hike fell from about 82.7% to about 69.1% as the tape broke — the selloff itself did what the data wouldn't.
Three beats to close the arc. What got tested: the assumption underneath the whole AI trade — that permits, power, and politics would keep up with the spending. What got hit: the suppliers, in size — chips down 12%, memory down 17%, and roughly $2.5 trillion off the Nasdaq in a single session. What is still standing: the buyers. Microsoft, Amazon, Alphabet and Meta fell 2 to 4% — real money, but a different league from their suppliers — and the labor market, which printed its lowest claims number since 1969 on the morning of the rout. And the one forward line: today at 8:30 a.m. Eastern the October jobs report lands — about 65,000 jobs expected after September's 29,000, unemployment expected steady at 4.2%, and wage growth expected to slip to 2.9% a year, below 3% for the first time since May 2021 — and after Thursday, a hot print is the one thing this tape does not need.
The earnings desk
Thursday before the open, the beats were real and the tape didn't care. ConocoPhillips earned $3.27 a share adjusted against about $2.97 expected, on production of 2.302 million barrels of oil equivalent a day and a realized price of $61.40, up 32% from a year ago — and it raised its dividend 11% to $0.93 a share and returned $3.4 billion to shareholders in the quarter. The stock still fell about 1%. Cigna beat cleanly: $7.98 a share against $7.52 expected, revenue of $73.79 billion against $72.64 billion, and it raised its full-year outlook to at least $30.60 a share. Cummins landed its earnings right in the expected range at $8.25 a share, but revenue of $9.44 billion, up 13%, came in light against the roughly $9.87 billion the Street had penciled in, and the shares fell about 4.9%. The day's one green exception was the consumer: Tapestry — Coach's parent — beat with $1.82 a share against $1.57 expected on sales of $1.89 billion, Coach revenue up 16%, and raised its full-year outlook; the stock jumped 7.07% to $134.17, the conspicuous winner of the day. Ralph Lauren beat too — $4.64 against $4.27, revenue up 9.1% to $2.19 billion — and was sold anyway, down 7.35%. On a day like Thursday, a beat was not protection. It was just a smaller loss, or in Tapestry's case, the exception that proves it.
After the close, two names bucked the rout outright. Airbnb rose about 10% in extended trading: revenue up 19% to $4.87 billion against $4.75 billion expected, earnings of $3.16 a share against $2.85, nights and seats booked up 16% to 155 million, gross booking value up 21% to $27.7 billion, full-year revenue growth guidance raised to the high teens, and up to $12 billion more in buybacks authorized. Cloudflare climbed about 17% after hours on its fastest growth in nearly four years: revenue up 39% to $782.5 million against about $737 million expected, non-GAAP earnings of $0.38 against $0.34, and full-year guidance raised. Atlassian told the opposite story: it beat — revenue up 24% to $1.77 billion, adjusted earnings of $1.65 against $1.43 — and fell more than 17% after hours because subscription growth is forecast to slow to about 18.5% by fiscal year-end. Monster Beverage split the difference: sales up 16.7% to $2.56 billion, ahead of expectations, but gross margin down a point to 54.7% as aluminum costs bit. Today, alongside the jobs report, the notable reporters are Moderna — expected to post a loss of roughly $1.10 to $1.28 a share on about $885 to $890 million, judged on vaccine sales and whether guidance rises; Humana — expected around a $1.00 loss a share, judged on medical costs, the line that decides every health insurer this season; Vistra, judged on power demand from the very data-center buildout Thursday just repriced; and Oklo, the pre-revenue nuclear name that also tops today's oversold screen.
The invention spotlight
On Thursday, Johnson & Johnson won FDA accelerated approval for Rybrevant Faspro — and for the patients in this corner of oncology, it is the first genuinely new option in a decade. The drug treats recurrent or metastatic head and neck squamous cell carcinoma that has already progressed after platinum chemotherapy and immunotherapy — a setting with almost nothing left to offer. It is the first therapy in this setting to hit two targets at once, EGFR and MET, two proteins these tumors use to grow. In the OrigAMI-4 trial, 42% of patients saw their tumors shrink or disappear, including complete responses in 15%, and 56% of responders were still responding at six months. It is also given as a five-minute injection under the skin instead of a long intravenous infusion. The honest limits: accelerated approval rests on response rate, not yet on proven longer survival — a confirmatory Phase 3 trial, OrigAMI-5, still has to deliver — and the approval excludes HPV-associated oropharyngeal cancers. A first new drug in ten years, with the receipts still to come. That is exactly what a real spotlight looks like.
The oversold corner
The screen re-ran this morning on 127 assets — large caps, midcaps, microcaps and the top cryptos, from Yahoo Finance and CoinGecko daily closes — and 34 meet all three tests, more than double yesterday's 15, because Thursday's rout dragged whole sectors across the line at once. Oklo still tops it, and deeper: $19.20, RSI 18.6, 50.1% below its 90-day average — a pre-revenue nuclear story stock with no earnings floor under it, reporting today into the worst possible tape. Intel is second at $52.25, RSI 20.6, 47.3% below — Thursday took another tenth off a stock still carrying its historic earnings drop. Lam Research is the new name at $185.20, RSI 22.6, 38.5% below — chip equipment, sold with the rest of the semiconductor complex on Thursday's 12% index fall. D-Wave Quantum sits at $9.05, RSI 22.6, 46.2% below — speculative quantum, falling with everything speculative. And Marvell rounds out the five at $133.55, RSI 22.6, 41.3% below, after falling roughly 17% on Thursday alone. Two more facts worth the breath: Nvidia itself now flags on the screen, eighth overall at $181.60 with an RSI of 25.4 — when the biggest name in the trade meets an oversold screen, the rout was not selective — and Solana is the first coin to flag, at $90.06, RSI 31.1, 11.6% below its average. Oversold is a description, not a buy idea.
The BogusAPY angle
Two hooks, both straight out of Thursday. First: even the yield wrapper bled. BlackRock's staked Ethereum ETF lost $22 million on Thursday as part of roughly $530 million that left U.S. spot Bitcoin and Ethereum ETFs in one day — and the math is the script. A staking yield of a couple percent a year does not cushion a 7.7% down day in the token it is paid in. Where does the yield come from? New tokens, paid for securing the network. How is it distributed? In those same falling tokens, minus fund fees — while the exit door stays wide open and holders used it. Any advertised APY that quotes the staking rate without the token's price risk is telling you half the story, and Thursday priced the other half. Second hook: Thursday repriced every cash flow that depends on a data center getting built — miners, GPU clouds, hosting deals. Yesterday this brief flagged a Bitcoin miner signing a $28 billion lease to an AI lab as the "real revenue" gold standard. It still is real revenue — but Thursday's lesson is that real revenue can still sit behind a permit. If a platform's yield depends on a buildout, the BogusAPY question gets a third leg: who can say no to the buildout — a governor, a county, a Congress — and what happens to the payout when they do?
Get posts like this by email: Subscribe to BogusAPY
Follow BogusAPY on X: @BogusAPY
Sources: Reuters and AP via Market Briefer, Seoul Economic Daily, The Retest and LSE (Nov 5 closes: Dow 51,523.06 −3.44% / −1,833.06 points, worst day since April 2025; S&P 500 7,353.73 −4.36%; Nasdaq Composite 24,315.00 −5.52%, correction, 11.9% below its Oct 6 record of 27,599.89; Nasdaq 100 −6.36% to 26,629.81; Russell 2000 −4.45% to 2,729.89; Philadelphia Semiconductor Index −12.25% to 9,011.14, second-biggest fall on record, worst since March 2020; all 11 S&P sectors down, technology −7.3%; SanDisk −22.26%, Micron −17.46%, AMD −17.26%, Nvidia −9.26% to $181.60, Qualcomm −9.49% to $156.75; VIX 28.09, up about 69% from 16.61; roughly $2.5T off the Nasdaq), Reuters via Datafloq and Macroplane (data-center slowdown as the lasting election theme — JonesTrading's Michael O'Rourke; UBS estimate that ~30% of expected 2028 U.S. data-center capacity additions could face construction pauses; Texas ~27% of planned U.S. capacity per Wells Fargo via CNBC; states likely to add restrictions ~45% of planned capacity per Goldman Sachs; New York's July permit pause of up to one year; Nasdaq-100 correction on Nov 2–3 amid AI-spending payback worries), Reuters via LSE (Brent settled $98.29 +$3.67 / +3.88%, WTI settled $90.52 +$2.40 / +2.72% on Nov 5, reversing Wednesday's 8%+ fall; at least five tanker incidents since Sunday per UKMTO, attacks running close to record pace; Eurasia Group cut renewed U.S. strike odds on Iran to 60% from 65%), Labor Department via Market Briefer (initial claims −6,000 to 189,000 for the week ended Oct 31, lowest since 1969, vs 196,000 forecast; Q3 nonfarm productivity +3.6% vs 2.8% forecast; unit labor costs −0.7%), CoinGecko via KuCoin, CoinStats and Analytics Insight (Nov 6, ~00:00 UTC: BTC $76,087.90 −5.49%; ETH $2,238.01 −7.70%; total crypto market cap ~$2.55T, down ~5%), Alternative.me via FXStreet and CoinStats (Fear & Greed 28, Fear, down from 50 Neutral), Farside Investors via KuCoin and Blockchain.News (Nov 5: Bitcoin ETF outflows $430.2M — FBTC −$199.9M, IBIT −$105.0M, GBTC −$49.9M, none of the 12 funds positive; Ethereum ETF outflows ~$100.0M — ETHA −$75.2M, staked ETHB −$22.0M), CoinGlass via CryptoCompass and Coin-Turk (more than $1B liquidated in 24 hours, longs the bulk), CME FedWatch via KuCoin/Odaily (December hike odds 69.1%, down from 82.7% the prior day), Reuters economist survey via SRN and FXStreet (October jobs report due Nov 6, 8:30 a.m. ET: payrolls +65,000 expected vs +29,000 in September, unemployment 4.2% expected, average hourly earnings +0.3% m/m and +2.9% y/y — below 3% for the first time since May 2021), ConocoPhillips, Cigna, Cummins, Tapestry, Ralph Lauren, Airbnb, Cloudflare, Atlassian and Monster Beverage reports via company releases, Reuters and Market Briefer (COP adjusted EPS $3.27 vs ~$2.97 LSEG, production 2,302 MBOED, realized price $61.40 +32% y/y, dividend raised 11% to $0.93, $3.4B returned in the quarter, shares ~−1%; CI adjusted EPS $7.98 vs $7.52, revenue $73.79B vs $72.64B, FY outlook raised to at least $30.60; CMI EPS $8.25, revenue $9.44B +13%, shares −4.93% to $448.58; TPR adjusted EPS $1.82 vs $1.57, sales $1.89B vs $1.86B, Coach revenue +16%, FY27 outlook raised, shares +7.07% to $134.17; RL adjusted EPS $4.64 vs $4.27, revenue $2.19B +9.1%, shares −7.35%; ABNB revenue $4.87B +19% vs $4.75B, EPS $3.16 vs $2.85, nights/seats 155.0M +16%, GBV $27.7B +21%, FY growth guide raised to high teens, Q4 guide $3.22–3.28B, +$12B buyback authorization, shares ~+10% extended; NET revenue $782.5M +39% vs ~$737M, non-GAAP EPS $0.38 vs $0.34, GAAP net loss $34.1M, FCF $82.1M, FY guidance raised, shares ~+17% extended; TEAM revenue $1.77B +24% vs $1.71B, adjusted EPS $1.65 vs $1.43, cloud revenue +31%, FCF $463M, subscription ARR growth slowing to ~18.5% by FY-end, shares −17%+ extended; MNST net sales $2.56B +16.7%, adjusted EPS $0.30, gross margin 54.7% −100bp), earnings calendars via TipRanks, MarketBeat and TipRanks earnings previews (Nov 6 BMO: MRNA expected loss ~$1.10–1.28 on ~$885–890M; HUM expected loss ~$1.00–1.01; plus VST and OKLO), Johnson & Johnson release and FDA approval notice, Nov 5 (Rybrevant Faspro accelerated approval for recurrent/metastatic HNSCC after platinum chemotherapy and anti-PD-(L)1 therapy; first dual EGFR–MET-targeted therapy in this setting; OrigAMI-4 ORR 42%, complete responses 15%, 56% of responders with duration of response ≥6 months; confirmatory Phase 3 OrigAMI-5 ongoing; not indicated for HPV-associated OPSCC), Yahoo Finance and CoinGecko (oversold screener, 127 assets, 34 flagged). Not financial advice.
Comments
Post a Comment